Hari M - Search Results

1

Paclitaxel resistance by random mutagenesis of α-tubulin.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Among authors: hari m. Cytoskeleton (Hoboken). 2013 Dec;70(12):849-62. doi: 10.1002/cm.21154. Epub 2013 Nov 15. Cytoskeleton (Hoboken). 2013. PMID: 24155014 Free article.

2

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.

Hari M, Wang Y, Veeraraghavan S, Cabral F. Hari M, et al. Mol Cancer Ther. 2003 Jul;2(7):597-605. Mol Cancer Ther. 2003. PMID: 12883031

3

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.

Hari M, Yang H, Zeng C, Canizales M, Cabral F. Hari M, et al. Cell Motil Cytoskeleton. 2003 Sep;56(1):45-56. doi: 10.1002/cm.10132. Cell Motil Cytoskeleton. 2003. PMID: 12905530

4

Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Among authors: hari m. Pharm Res. 2012 Nov;29(11):2994-3006. doi: 10.1007/s11095-012-0794-5. Epub 2012 Jun 6. Pharm Res. 2012. PMID: 22669706

5

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM. Hari M, et al. Mol Cancer Ther. 2006 Feb;5(2):270-8. doi: 10.1158/1535-7163.MCT-05-0190. Mol Cancer Ther. 2006. PMID: 16505100

6

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM. Loganzo F, et al. Among authors: hari m. Cancer Res. 2003 Apr 15;63(8):1838-45. Cancer Res. 2003. PMID: 12702571

7

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM. Loganzo F, et al. Among authors: hari m. Mol Cancer Ther. 2004 Oct;3(10):1319-27. Mol Cancer Ther. 2004. PMID: 15486199

8

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.

Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA Jr, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, Ayral-Kaloustian S, Zask A, Greenberger LM. Nunes M, et al. Among authors: hari m. Biochemistry. 2005 May 10;44(18):6844-57. doi: 10.1021/bi0474766. Biochemistry. 2005. PMID: 15865430

9

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.

Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C. Sampath D, et al. Among authors: hari m. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69. doi: 10.1158/1078-0432.CCR-05-2349. Clin Cancer Res. 2006. PMID: 16740771

10

Comparative molecular profiling of multidrug-resistant Pseudomonas aeruginosa identifies novel mutations in regional clinical isolates from South India.

Menon ND, Somanath P, Jossart J, Vijayakumar G, Shetty K, Baswe M, Chatterjee M, Hari MB, Nair S, Kumar VA, Nair BG, Nizet V, Perry JJP, Kumar GB. Menon ND, et al. Among authors: hari mb. JAC Antimicrob Resist. 2024 Jan 16;6(1):dlae001. doi: 10.1093/jacamr/dlae001. eCollection 2024 Feb. JAC Antimicrob Resist. 2024. PMID: 38230352 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page